ZA200603538B - P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same - Google Patents
P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the sameInfo
- Publication number
- ZA200603538B ZA200603538B ZA200603538A ZA200603538A ZA200603538B ZA 200603538 B ZA200603538 B ZA 200603538B ZA 200603538 A ZA200603538 A ZA 200603538A ZA 200603538 A ZA200603538 A ZA 200603538A ZA 200603538 B ZA200603538 B ZA 200603538B
- Authority
- ZA
- South Africa
- Prior art keywords
- same
- pharmaceutical composition
- preparing
- glycoprotein inhibitor
- anticancer agent
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940049937 Pgp inhibitor Drugs 0.000 title 1
- 239000002748 glycoprotein P inhibitor Substances 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Ceramic Engineering (AREA)
- Health & Medical Sciences (AREA)
- Manufacturing & Machinery (AREA)
- General Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030069582A KR100557093B1 (ko) | 2003-10-07 | 2003-10-07 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200603538B true ZA200603538B (en) | 2007-09-26 |
Family
ID=36500896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200603538A ZA200603538B (en) | 2003-10-07 | 2006-05-04 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7625926B2 (xx) |
| EP (1) | EP1678162B1 (xx) |
| JP (1) | JP4481992B2 (xx) |
| KR (1) | KR100557093B1 (xx) |
| CN (1) | CN1863795B (xx) |
| AT (1) | ATE466008T1 (xx) |
| AU (1) | AU2004277475B2 (xx) |
| BR (1) | BRPI0415053B8 (xx) |
| CA (1) | CA2541301C (xx) |
| DE (1) | DE602004026903D1 (xx) |
| DK (1) | DK1678162T3 (xx) |
| ES (1) | ES2342290T3 (xx) |
| IL (1) | IL174665A (xx) |
| MX (1) | MXPA06003803A (xx) |
| NO (1) | NO336127B1 (xx) |
| NZ (1) | NZ546257A (xx) |
| PL (1) | PL1678162T3 (xx) |
| PT (1) | PT1678162E (xx) |
| RU (1) | RU2317985C1 (xx) |
| SI (1) | SI1678162T1 (xx) |
| WO (1) | WO2005033097A1 (xx) |
| ZA (1) | ZA200603538B (xx) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06009019A (es) * | 2004-02-18 | 2007-03-08 | Astrazeneca Ab | Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotropico. |
| GB0700773D0 (en) * | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| AU2008221263B2 (en) * | 2007-03-01 | 2012-02-23 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| GB0706072D0 (en) * | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| RS54506B1 (sr) | 2008-09-02 | 2016-06-30 | Novartis Ag | Derivati pikolinamida kao inhibitori kinaza |
| KR101466245B1 (ko) * | 2010-01-15 | 2014-12-01 | 한미사이언스 주식회사 | 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물 |
| US9173883B2 (en) | 2012-05-21 | 2015-11-03 | Novartis Ag | Ring-substituted N-pyridinyl amides as kinase inhibitors |
| KR101986683B1 (ko) * | 2012-12-13 | 2019-06-10 | 한미약품 주식회사 | 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체 |
| CN103804352B (zh) * | 2014-01-23 | 2017-06-13 | 中国药科大学 | 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用 |
| KR20150135110A (ko) * | 2014-05-23 | 2015-12-02 | 한미정밀화학주식회사 | p-당단백질의 저해제 및 p-당단백질의 기질 약물을 포함하는 약제학적 조성물 |
| CN104327046B (zh) * | 2014-10-14 | 2017-11-17 | 中国药科大学 | 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用 |
| JO3737B1 (ar) * | 2015-07-21 | 2021-01-31 | Athenex Therapeutics Ltd | تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان |
| TWI752750B (zh) | 2015-09-30 | 2022-01-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
| WO2019200290A1 (en) * | 2018-04-13 | 2019-10-17 | Athenex Therapeutics Limited | Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma |
| US10849893B2 (en) | 2018-12-14 | 2020-12-01 | Athenex HK Innovative Limited | Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancer |
| TWI845578B (zh) * | 2018-12-14 | 2024-06-21 | 香港商慧源香港創新有限公司 | 用於治療癌症之口服愛萊諾迪肯（ｉｒｉｎｏｔｅｃａｎ）與Ｐ－ｇｐ抑制劑的醫療組合 |
| WO2020168144A1 (en) | 2019-02-14 | 2020-08-20 | Teva Pharmaceuticals International Gmbh | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(lh)- isoquinolinyl)ethyl] phenyl }-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl] -4- oxo-4h-chromene-2-carboxamide and of its mesylate salt |
| WO2020230037A1 (en) * | 2019-05-13 | 2020-11-19 | Dr. Reddy's Laboratories Limited | Alternate process for the preparation of encequidar |
| WO2021044350A1 (en) * | 2019-09-04 | 2021-03-11 | Dr. Reddy’S Laboratories Limited | Solid forms of encequidar mesylate and processes thereof |
| US20230278990A1 (en) | 2020-07-10 | 2023-09-07 | Teva Czech Industries S.R.O | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt |
| CA3194694A1 (en) | 2020-10-07 | 2022-04-14 | Sameer Urgaonkar | Acetamido-phenyltetrazole derivatives and methods of using the same |
| EP4237420A4 (en) | 2020-10-30 | 2025-03-19 | Health Hope Pharma Limited | Polymorphisms of hm30181 mesylate |
| CN117603219B (zh) * | 2023-11-29 | 2025-08-08 | 浙江大学 | 一种p-糖蛋白抑制剂及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT64533A (en) * | 1990-11-06 | 1994-01-28 | Pfizer | Method for producing quinazoline derivatives for improving anti-tumoric activity and preparations containing said compounds |
| JP3223193B2 (ja) | 1991-08-09 | 2001-10-29 | 株式会社日清製粉グループ本社 | インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質 |
| EP0649410B1 (en) | 1992-07-10 | 1997-05-02 | Laboratoires Glaxo Sa | Anilide derivatives |
| GB9717576D0 (en) * | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
| CA2400264A1 (en) * | 2000-02-15 | 2001-08-23 | Teijin Limited | Cancer remedy comprising anthranilic acid derivative as active ingredient |
| KR101060971B1 (ko) | 2002-05-14 | 2011-09-01 | 제노바 리미티드 | 안트라닐산 유도체 수화물의 제조 방법 |
| KR100580743B1 (ko) | 2003-10-08 | 2006-05-15 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 신규한 크로몬 유도체 또는이의 약제학적으로 허용가능한 염 및 이들의 제조 방법 |
-
2003
- 2003-10-07 KR KR1020030069582A patent/KR100557093B1/ko not_active Expired - Lifetime
-
2004
- 2004-10-06 MX MXPA06003803A patent/MXPA06003803A/es active IP Right Grant
- 2004-10-06 WO PCT/KR2004/002550 patent/WO2005033097A1/en not_active Ceased
- 2004-10-06 DK DK04774778.7T patent/DK1678162T3/da active
- 2004-10-06 DE DE602004026903T patent/DE602004026903D1/de not_active Expired - Lifetime
- 2004-10-06 NZ NZ546257A patent/NZ546257A/en not_active IP Right Cessation
- 2004-10-06 CN CN2004800293562A patent/CN1863795B/zh not_active Expired - Lifetime
- 2004-10-06 AT AT04774778T patent/ATE466008T1/de active
- 2004-10-06 AU AU2004277475A patent/AU2004277475B2/en not_active Expired
- 2004-10-06 SI SI200431434T patent/SI1678162T1/sl unknown
- 2004-10-06 US US10/574,098 patent/US7625926B2/en active Active
- 2004-10-06 EP EP04774778A patent/EP1678162B1/en not_active Expired - Lifetime
- 2004-10-06 JP JP2006532094A patent/JP4481992B2/ja not_active Expired - Lifetime
- 2004-10-06 PT PT04774778T patent/PT1678162E/pt unknown
- 2004-10-06 ES ES04774778T patent/ES2342290T3/es not_active Expired - Lifetime
- 2004-10-06 PL PL04774778T patent/PL1678162T3/pl unknown
- 2004-10-06 BR BRPI0415053A patent/BRPI0415053B8/pt not_active IP Right Cessation
- 2004-10-06 CA CA002541301A patent/CA2541301C/en not_active Expired - Lifetime
- 2004-10-06 RU RU2006114427/04A patent/RU2317985C1/ru active
-
2006
- 2006-03-30 IL IL174665A patent/IL174665A/en active IP Right Grant
- 2006-05-04 ZA ZA200603538A patent/ZA200603538B/xx unknown
- 2006-05-05 NO NO20062019A patent/NO336127B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200603538B (en) | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same | |
| MXPA05009985A (es) | Ligandos de receptores de canabinoides. | |
| UA96449C2 (xx) | Стабільні препарати лаквінімоду$стабильные препараты лаквинимода | |
| GB9914486D0 (en) | Medicaments | |
| ATE450533T1 (de) | Carboxamidderivate | |
| MXPA04005877A (es) | Composiciones farmaceuticas de derivados de taxano oralmente activos con biodisponibilidad mejorada. | |
| MXPA03010761A (es) | Combinaciones farmaceuticas. | |
| DE602004011966D1 (en) | Heterocyclylverbindungen | |
| GB0109122D0 (en) | Novel compounds | |
| UA86776C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение | |
| AU2003239389A1 (en) | Opioid receptor antagonists | |
| WO2004071374A3 (en) | Once a day orally administered pharmaceutical compositions | |
| WO2005117895A8 (en) | Compositions comprising meloxicam | |
| TNSN06220A1 (en) | Benzimidazole derivatives | |
| MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides | |
| SI1750703T1 (sl) | Postopek za zmanjšanje gastrointestinalne toksičnosti zaradi dajanja tegafurja | |
| AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments | |
| NO20031410L (no) | Anvendelse av distamycinderivater for fremstilling av medikamenter | |
| WO2003089449A3 (fr) | Composes aminoalkylsteroles avec activite anti-tumeur et neuroprotective | |
| WO2005013935A3 (en) | Composition for releasing a weak base for an extended period of time | |
| TW200510370A (en) | Urea derivatives | |
| WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
| AU2003281468A1 (en) | P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient | |
| AU2001244999A1 (en) | Naphthamide neurokinin antagonists for use as medicaments | |
| TW200626567A (en) | Benzoxazine and quinoxaline derivatives and uses |